As lawmakers, we share a responsibility to improve the lives of our constituents. For us, this mission is deeply personal. Our own families’ battles with mental health have shown us the critical need for new innovative therapies. With possible FDA-approval for psilocybin treatments on the horizon, there may be hope for Pennsylvanians struggling with severe mental health conditions.
​
Early, but promising, data has demonstrated the safety and efficacy of psilocybin, when prescribed and administered by trained and licensed medical professionals, for the treatment of certain serious mental health disorders. Pennsylvania’s patients with difficult-to-treat mental health conditions should have access to new, innovative treatments approved by the FDA as quickly as possible after approval. 

Yet, Pennsylvania’s current scheduling process will delay access to these FDA-approved, DEA-rescheduled therapies, and will prolong the suffering of those in need unless our law is updated.

This legislation ensures timely access to groundbreaking new treatments by aligning state scheduling laws with federal FDA approval and DEA decisions. It applies only to FDA-approved, pharmaceutical-grade psilocybin, administered under strict medical supervision, and that can also be covered by patient insurance. Importantly, it does not decriminalize or legalize natural psilocybin or non-approved substances.

Please join us in working to ensure our constituents have timely access to life-changing and innovative mental health treatments by sponsoring this legislation.
 

Statutes/Laws affected:
Printer's No. 1678 (May 12, 2025): P.L.233, No.64